Range Biotechnologies

Executive Summary

Range Biotechnologies is a San Francisco-based private biotechnology company founded in 2021, focused on developing an end-to-end solution for translational proteomics. The company aims to capture the molecular state of individuals to enable health monitoring, disease prevention, and improved health outcomes, with the goal of moving proteomics from a research tool into clinical diagnostics and personalized health. By leveraging advances in proteomics, Range Biotechnologies seeks to create a comprehensive platform that translates protein-level data into actionable insights for both patients and healthcare providers. The company is in the early stages of development, with no disclosed funding or valuation, and operates in the competitive landscape of genomics and gene therapy. Its success will depend on technological differentiation, clinical validation, and strategic partnerships to navigate the path from research to clinical adoption.

Upcoming Catalysts (preview)

• TBDSeries A or Seed Funding Announcement60% success
• Q4 2026Strategic Partnership with Diagnostics or Pharma Company40% success
• Q2 2027First Publication or Proof-of-Concept Data on Proteomics Platform50% success